Phase I trial of Total Marrow and Lymphoid Irradiation Transplantation Conditioning

Phase I trial of Total Marrow and Lymphoid Irradiation Transplantation Conditioning - Phase I trial of Total Marrow and Lymphoid Irradiation Transplantation Conditioning

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000037581

Enrollment

Registered

2019-08-02

Start date

2019-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematologic malignancy

Interventions

TMLI 14-18Gy/6fr

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with hematologic malignancy who are planned HSCT using myeloablative conditioning regimen. 2. Age between 20 and 60. 3. PS 0-2 4. Major organ function is maintained 5. Written informed consent

Exclusion criteria

Exclusion criteria: 1. with active extramedullary lesion 2. disease status is non-CR 3. with active another malignant disease 4. Restlessness 5. with pregnant or possible pregnant 6. with once or more HSCT history 7. Serious medical or psychological problems

Design outcomes

Primary

Measure	Time frame
Dose limited toxicities until 100 days after irradiation.	—

Countries

Japan

Contacts

Public ContactHiroaki Ogawa

Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Radiation Oncology

hogawa@cick.jp03-3823-2101

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026